These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34553222)

  • 1. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.
    Whooley J; Alazzawi M; Donlon NE; Bolger JC; Robb WB
    Dis Esophagus; 2022 May; 35(5):. PubMed ID: 34553222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM; Gong J; Klempner SJ; Chao J
    World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
    J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
    Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
    Zheng Z; Guo Y; Zou CP
    Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
    Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
    BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies.
    Chen M; Li C; Sun M; Li Y; Sun X
    Front Immunol; 2022; 13():1043517. PubMed ID: 36505480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
    Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Gastric Cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
    Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
    J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade in esophagogastric cancer.
    Cohen NA; Strong VE; Janjigian YY
    J Surg Oncol; 2018 Jul; 118(1):77-85. PubMed ID: 29878357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to use anti-PD-1 therapy in gastric cancer: the approach in the United States.
    Ilson DH
    Chin Clin Oncol; 2024 Feb; 13(1):7. PubMed ID: 38453657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
    Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
    Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
    Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
    JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.